With the recent trials such as SELECT and STEP-HFpEF demonstrating benefits of GLP1-agonists in terms of CV risk reduction and improved exercise function, have you begun to incorporate this class of medications into routine CV health maintenance for patients with HFpEF and/or pre-existing CAD?

I would strongly support the use of this medication. The biggest challenge is insurance coverage. When would it be approved by insurance and how many hoops we will need to jump before they approve it?

Established CV disease listening to the podcast MI, stroke or CHF, and BMI greater than 27 were inclusion criteria and reported benefits.

I am not certain if hypertensive heart disease qualifies in this category (being cardiovascular disease and with high prevalence of HFpEF) and if it does, it trul...